Discover
EIKN
Eikon Therapeutics, Inc. Common Stock
9.91
1 x 7.65
1 x 10.50
bid
ask
+
0.00
0.00%
100 @ 04:00 PM
9.75 -0.16 (1.61%)
| Ytd | -33.93% | |
| 1y | -33.93% |
day range
7.90
52 week range
17.40
| Open | Prev Close | 9.91 | Low | High | Mkt Cap | 29.24M | |||
| Vol | 0.00 | Avg Vol | 360.21K | EPS | -29.46 | P/E | -0.34 | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 10.46 | 200-d Avg | 11.33 | 1yr Est | 0.00 |
| Income Statement | |||
| Operating Expenses | 87.34M | ||
| Research and Development Expense | 70.05M | ||
| Selling, General and Administrative Expense | 17.29M | ||
| Operating Income | -87.34M | ||
| Interest Expense | -4.38M | ||
| Net Income | -82.96M | ||
| Net Income Common Stock | -82.96M | ||
| Net Income Common Stock (USD) | -82.96M | ||
| Consolidated Income | -82.96M | ||
| Earnings per Basic Share | -2.46 | ||
| Earnings per Basic Share (USD) | -2.46 | ||
| Earnings per Diluted Share | -2.46 | ||
| Earning Before Interest & Taxes (EBIT) | -87.34M | ||
| Earning Before Interest & Taxes (USD) | -87.34M | ||
| Weighted Average Shares | 33.70M | ||
| Weighted Average Shares Diluted | 33.70M | ||
| Balance Sheet | |||
| Cash and Equivalents | 161.55M | ||
| Cash and Equivalents (USD) | 161.55M | ||
| Investments | 442.66M | ||
| Investments Current | 351.03M | ||
| Investments Non-Current | 91.64M | ||
| Current Assets | 529.50M | ||
| Property, Plant & Equipment Net | 229.13M | ||
| Total Assets | 850.83M | ||
| Debt Current | 9.74M | ||
| Total Debt | 254.83M | ||
| Current Liabilities | 45.06M | ||
| Debt Non-Current | 245.09M | ||
| Total Liabilities | 300.15M | ||
| Accumulated Retained Earnings (Deficit) | -1.00B | ||
| Shareholders Equity | 550.67M | ||
| Shareholders Equity (USD) | 550.67M | ||
| Assets Non-Current | 321.33M | ||
| Total Debt (USD) | 254.83M | ||
| Liabilities Non-Current | 255.09M | ||
| Trade and Non-Trade Payables | 6.01M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 5.11M | ||
| Net Cash Flow from Financing | 349.31M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 56.29M | ||
| Capital Expenditure | -262.00K | ||
| Issuance (Purchase) of Equity Shares | 349.31M | ||
| Net Cash Flow from Investing | -203.22M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -202.95M | ||
| Net Cash Flow from Operations | -89.80M | ||
| Share Based Compensation | 2.78M | ||